<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041652</url>
  </required_header>
  <id_info>
    <org_study_id>IM-T-hMN14-04</org_study_id>
    <nct_id>NCT00041652</nct_id>
  </id_info>
  <brief_title>Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer</brief_title>
  <official_title>A Phase I/II Clinical Trial of Immunotherapy With Humanized MN-14 IgG in Recurrent, Metastatic, Unresectable Colorectal and Breast Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the safety of hMN14 at different dose levels in the&#xD;
      treatment of either colorectal or breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date>June 2003</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMN14 (labetuzumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Disease Characteristics:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma&#xD;
&#xD;
          -  Measurable lesion diagnosed by CT scan&#xD;
&#xD;
          -  Recurrent/metastatic disease considered surgically unresectable.&#xD;
&#xD;
        Prior/Concurrent Therapy:&#xD;
&#xD;
          -  Chemotherapy: Patients who either have failed at least one regimen of standard&#xD;
             systemic therapy, or are clinically asymptomatic and are not presently being&#xD;
             considered for chemotherapy (Enrollment must occur at least 4 weeks beyond last&#xD;
             treatment)&#xD;
&#xD;
          -  Other: Prior treatment with investigational agents is excluded unless follow-up is&#xD;
             completed and patient is off study&#xD;
&#xD;
        Patient Characteristics/Inclusion Criteria:&#xD;
&#xD;
          -  Performance Status: Patients with a Karnofsky performance status &gt; 70% (or equivalent,&#xD;
             ECOG 0-1) and expected survival of at least 3 months.&#xD;
&#xD;
          -  Hematopoietic: WBC &gt;/= 3000 mm3, neutrophils &gt;/= 1500 mm3, platelets &gt;/= 75,000, CEA &lt;&#xD;
             300 ng/mL&#xD;
&#xD;
          -  Hepatic: Serum bilirubin &lt;/= 2.0 mg/dL, ALT &lt; 2.5 x IULN&#xD;
&#xD;
          -  Cardiovascular: Patients with LVEF &gt;/= 40% by required MUGA/2D-ECHO study.&#xD;
&#xD;
          -  Pulmonary: Patients with FEV1 &gt;/= 60% by required Pulmonary Function Tests&#xD;
&#xD;
          -  Other: Patients agreeing to use a medically effective method of contraception during&#xD;
             and for a period of 3 months after the treatment period. A pregnancy test will be&#xD;
             preformed on each premenopausal female of childbearing potential immediately prior to&#xD;
             entry into the study. Patients able to understand and give written informed consent.&#xD;
             Patients with a significant concurrent medical condition that could affect the&#xD;
             patient's ability to tolerate or complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence Rugg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lauri Welles, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Cancer Center</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <study_first_submitted>July 11, 2002</study_first_submitted>
  <study_first_submitted_qc>July 12, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2002</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Colorectal Carcinoma</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labetuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

